Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Wenwei Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7292-5980; OpenAlex author ID A5019710866. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 3

  1. Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer. Co-author DOI 10.1186/s12885-025-13799-5↗
  2. Recent advances in targeted therapy for pancreatic adenocarcinoma. First author DOI 10.4251/wjgo.v15.i4.571↗
  3. Long-term survival of a patient with pancreatic cancer and lung metastasis: A case report and review of literature. Co-author DOI 10.12998/wjcc.v9.i30.9134↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongkun Sun · 2 shared papers, 2021–2023 · strength 0.46
  2. Yuting Fang · 1 shared paper, 2023 · strength 0.26
  3. Biyang Cao · 1 shared paper, 2025 · strength 0.22
  4. Wen Zhang · 1 shared paper, 2025 · strength 0.22
  5. Letian Zhang · 1 shared paper, 2025 · strength 0.22
  6. Xiaoting Ma · 1 shared paper, 2025 · strength 0.22
  7. Kai Ou · 1 shared paper, 2025 · strength 0.22
  8. Lin Yang · 1 shared paper, 2025 · strength 0.22
  9. Haizhen Lu · 1 shared paper, 2021 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.